251 related articles for article (PubMed ID: 32032581)
1. The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells.
Piwarski SA; Thompson C; Chaudhry AR; Denvir J; Primerano DA; Fan J; Salisbury TB
Biochem Pharmacol; 2020 Apr; 174():113845. PubMed ID: 32032581
[TBL] [Abstract][Full Text] [Related]
2. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.
Rowland LK; Campbell PS; Mavingire N; Wooten JV; McLean L; Zylstra D; Thorne G; Daly D; Boyle K; Whang S; Unternaehrer J; Brantley EJ
J Cell Biochem; 2019 Apr; 120(4):6004-6014. PubMed ID: 30450577
[TBL] [Abstract][Full Text] [Related]
3. The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma.
Zhang X; He B; Chen E; Lu J; Wang J; Cao H; Li L
J Cell Physiol; 2021 Jan; 236(1):178-192. PubMed ID: 32510618
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells.
Brinkman AM; Wu J; Ersland K; Xu W
BMC Cancer; 2014 May; 14():344. PubMed ID: 24885022
[TBL] [Abstract][Full Text] [Related]
5. ITE, an endogenous aryl hydrocarbon receptor ligand, suppresses endometrial cancer cell proliferation and migration.
Bian Y; Li Y; Shrestha G; Wen X; Cai B; Wang K; Wan X
Toxicology; 2019 Jun; 421():1-8. PubMed ID: 30953668
[TBL] [Abstract][Full Text] [Related]
6. AhR ligands reactivate LINE-1 retrotransposon in triple-negative breast cancer cells MDA-MB-231 and non-tumorigenic mammary epithelial cells NMuMG.
Miret N; Zappia CD; Altamirano G; Pontillo C; Zárate L; Gómez A; Lasagna M; Cocca C; Kass L; Monczor F; Randi A
Biochem Pharmacol; 2020 May; 175():113904. PubMed ID: 32156659
[TBL] [Abstract][Full Text] [Related]
7. Aryl hydrocarbon receptor (AHR) regulation of L-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells.
Tomblin JK; Arthur S; Primerano DA; Chaudhry AR; Fan J; Denvir J; Salisbury TB
Biochem Pharmacol; 2016 Apr; 106():94-103. PubMed ID: 26944194
[TBL] [Abstract][Full Text] [Related]
8. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
9. Activation of Aryl Hydrocarbon Receptor by ITE Improves Cardiac Function in Mice After Myocardial Infarction.
Seong E; Lee JH; Lim S; Park EH; Kim E; Kim CW; Lee E; Oh GC; Choo EH; Hwang BH; Kim CJ; Ihm SH; Youn HJ; Chung WS; Chang K
J Am Heart Assoc; 2021 Jul; 10(13):e020502. PubMed ID: 34157850
[TBL] [Abstract][Full Text] [Related]
10. [JAG1 affects monocytes-macrophages to reshape the pre-metastatic niche of triple-negative breast cancer through LncRNA MALAT1 in exosomes].
Xu M; Shi Y; Liu J; Wu M; Zhang F; He Z; Tang M
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1525-1535. PubMed ID: 37814867
[TBL] [Abstract][Full Text] [Related]
11. The Aryl Hydrocarbon Receptor Undergoes Chaperone-Mediated Autophagy in Triple-Negative Breast Cancer Cells.
Chen J; Yang Y; Russu WA; Chan WK
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562118
[TBL] [Abstract][Full Text] [Related]
12. TCDD and a putative endogenous AhR ligand, ITE, elicit the same immediate changes in gene expression in mouse lung fibroblasts.
Henry EC; Welle SL; Gasiewicz TA
Toxicol Sci; 2010 Mar; 114(1):90-100. PubMed ID: 19933214
[TBL] [Abstract][Full Text] [Related]
13. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis.
Jin UH; Lee SO; Pfent C; Safe S
BMC Cancer; 2014 Jul; 14():498. PubMed ID: 25011475
[TBL] [Abstract][Full Text] [Related]
14. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.
Stark K; Burger A; Wu J; Shelton P; Polin L; Li J
PLoS One; 2013; 8(9):e74525. PubMed ID: 24058584
[TBL] [Abstract][Full Text] [Related]
16. Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist.
Dolciami D; Gargaro M; Cerra B; Scalisi G; Bagnoli L; Servillo G; Fazia MAD; Puccetti P; Quintana FJ; Fallarino F; Macchiarulo A
ChemMedChem; 2018 Feb; 13(3):270-279. PubMed ID: 29266750
[TBL] [Abstract][Full Text] [Related]
17. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.
Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J
Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352
[TBL] [Abstract][Full Text] [Related]
18. Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy.
Masiero M; Li D; Whiteman P; Bentley C; Greig J; Hassanali T; Watts S; Stribbling S; Yates J; Bealing E; Li JL; Chillakuri C; Sheppard D; Serres S; Sarmiento-Soto M; Larkin J; Sibson NR; Handford PA; Harris AL; Banham AH
Mol Cancer Ther; 2019 Nov; 18(11):2030-2042. PubMed ID: 31395687
[TBL] [Abstract][Full Text] [Related]
19. A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo.
Henry EC; Bemis JC; Henry O; Kende AS; Gasiewicz TA
Arch Biochem Biophys; 2006 Jun; 450(1):67-77. PubMed ID: 16545771
[TBL] [Abstract][Full Text] [Related]
20. An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells.
Wang K; Li Y; Jiang YZ; Dai CF; Patankar MS; Song JS; Zheng J
Cancer Lett; 2013 Oct; 340(1):63-71. PubMed ID: 23851185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
